- Point of View: Overcoming barriers to affordability of orally inhaled products while protecting innovation
- Gaining new insights into pressurized metered dose inhaler (pMDI) design using synchrotron radiation
- Dry powder inhalers—More than 170 years of development; Where to next?
- Spray pattern as a screening tool during early development of nasal sprays
- Connected inhalers: Stakeholders’ potential benefits and possible concerns
- Nebulizers: Past to present platforms and future possibilities (2018)
- Back Page: Acoustic emission for characterization of inhaler performance
- Back Page: Modeling paradigms for orally inhaled drugs
- Back Page: Rules in pharmacy and music: More in common than you might believe!
- Regulatory considerations for cybersecurity and data privacy in digital health and medical applications and products
- Evaluating simulated patient use in realistic nasal airway models for the in vitro characterization of nasal spray products
- The importance of human factors in inhaler development: The making of PowdAir®
- The Good Cascade Impactor Practice (GCIP) Concept: A systematic approach to risk management of erroneous measurements in the assessment of inhaler emitted aerosol aerodynamic particle size distributions (APSDs)
- Significant restriction of the delivered dose uniformity criteria in the revised USP Chapter for Aerosols
- Selecting an MDI can
- Selecting a dose counter
- Redundancy Based Development (RBD) for a dry powder inhaler
- Quality by design: Considerations for inhalation product development
- Principles of nebulizer technology
- Parameters to consider in software for respiratory drug and device testing
- Overlooked opportunities for nebulizers in inhalation product development
- Opportunities for capsule-based DPIs in emerging markets
- Nebulizers: Past to present platforms and future possibilities (2016)
- Nasal spray regulatory approval
- Nasal drug delivery devices: Past, present and future device innovations for the would-be product developer
- Nasal and sublingual spray delivery devices: Market opportunities and unmet medical needs
- Measuring the cold freon effect
- Interaction of nanomaterials at the air-liquid interface of the lung
- Innovation in analytical tools: More signal and less noise in particle size testing of inhaled products
- Inhalation to the small airways
- Impact of capsule selection on formulation stability in dry powder inhalers (DPIs)
- Human factors studies in the development of a new nasal delivery device
- Human factors and inhalation pharmaceuticals: Manifestations, mitigations and regulatory issues
- Getting started with CFD
- Gaps in statistical approaches to control of delivered dose uniformity throughout product lifecycle
- Formulation concepts for small-volume nebulizers: Challenges and opportunities
- Formulation and characterization of nasal sprays
- Evolution of nasal aerosol products for pain management
- Enhancing drug product portfolios for nasal aerosols and buccal spray delivery systems
- Elastomers in orally inhaled and nasal drug products, Part II: Control strategies
- Elastomers in orally inhaled and nasal drug products, Part I: Elastomer selection and qualification
- E-cigarettes: Learnings for inhalation scientists
- DPI development: Understanding the technical challenges
- Developing OINDPs using Quality by Design
- Designing a DPI for multiple constituencies
- Design of an inhaler-specific robotic system for laboratory use in early development
- Delivery of inhaled bronchodilators by breath-actuated jet nebulizer: The potential for improved adherence with clinical guidelines
- Delivering orally inhaled medications to the older patient with COPD and/or asthma: A challenge in both device design and clinical approach
- Critical evaluation of the revised and new USP chapters for aerosols: and [Pharm Forum 2011; 37(4)]
- Considerations in selecting a contract manufacturing organization
- The pressurized metered dose inhaler: Past, present and future perspectives
- The role of intelligent sorbents in respiratory drug delivery devices
- Comparison between in vitro performance of the Child “Alberta” Idealized Throat and Ph.Eur./USP induction port for the delivery of salbutamol sulfate inhalation aerosol by pressurized metered dose inhaler
- Avoiding pitfalls obtaining inhalation patents at the European Patent Office
- Assessing the role of breathing simulators in OIP testing
- Addressing the patient-device use interface: Why patient-friendly features are important
- Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts: A partnership for the assurance of Oral Inhaled Product (OIP) quality
- A forensic approach to particulate contamination in inhalable drug products
- A “smart” move: The development of electronic devices for nasal aerosols
- In vitro particle deposition in the nasal cavity
- Spray pattern: A rapid and sensitive early development tool for respiratory drug products
- Addressing the patient-device use interface: Development and laboratory validation of a facemask with anatomically-responsive face models
- What is the future of HFA pMDIs? A patent-based perspective